63
Views
3
CrossRef citations to date
0
Altmetric
(RG) Obstetrics and Gynaecology

Hormone replacement therapy in postmenopausal women with benign fibrocystic mastopathy

, , , &
Pages 146-150 | Published online: 03 Jul 2009

References

  • Cole P, Elwood JM, Kaplan SD. Incidence rates and risk factors of benign breast neoplasms. Am J Epidemiol 1978;108:112
  • Hislop TJ, Elwood JM. Risk factors for benign breast disease. A 30 years cohort study. Can Med Assoc J 1981;124:283
  • Angeli A, Dogliotti L, Naldoni C, et al. Steroid biochemistry and categorization of breast cyst fluid: relation to breast cancer risk. J Steroid Biochem Mol Biol 1994;49:333–9
  • Dixon JM, McDonald C, Elton RA, Miller WR. Risk of breast cancer in women with palpable breast cysts: a prospective study. Lancet 1999; 353:1742–5
  • Plu-Bureau G, Thalabard JC. It is not advis-able to prescribe hormonal replacement therapy to a woman with proliferative masto-pathy with atypia. Gynecol Obstet Fertil 2002; 30:335–9
  • Espie M, Cuvier C, Perret F, Cottu PH. It is possible to prescribe a hormonal replacement therapy for a woman with proliferative masto-pathy with atypia. Gynecol Obstet Fertil 2002; 30:331–5
  • Erel CT, Erel G, Seyisoglu H, et al. Mammo-graphic density increase in women receiving different hormone replacement regimens. Maturitas 2001;40:151–7
  • Sendag F, Terek MC, Ozsener S, et al. Mammo-graphic density changes during postmenopausal hormone replacement therapies. Fertil Steril 2001;76:445–50
  • Egarter C, Eppel W, Vogel S, Wolf G. A pilot study of hormone replacement therapy with tibolone in women with mastopathic breasts. Maturitas 2001;40:165–71
  • Speroff L. The meaning of mammographic breast density in users of postmenopausal hormone therapy. Maturitas 2002;41:171–5
  • Van Gils CH, Otten JDM, Verbeek ALM, Hendriks JHCL, Holland R. Effect of mammo-graphic breast density on breast cancer screen-ing performance: a study in Nijmergen, The Netherlands. J Epidemiol Community Health 1998;52:267–71
  • Isabel J, Ortega D. Mammographic density in postmenopausal women treated with tibolone, estradiol or conventional hormone replacement therapy. Clin Drug Invest 2000;20:101–7
  • Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in heathy postmenopausal women. J Am Med Assoc 2002;288:321–33
  • Gompel A, Chaouat M, Jacob D, et al. In vitro studies of tibolone in breast cells. Fertil Steril 2002;78:351–9

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.